PFE241220P17000
- 0.00
- 0.000.00%
Pfizer Newsroom
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Should Value Investors Buy Pfizer (PFE) Stock?
Pfizer Inc. (PFE) Is Attracting Investor Attention: Here Is What You Should Know
Pfizer ($PFE) Stock Has Evolved Into a Solid Income Play
Pfizer's Colorectal Cancer Combo Therapy Gains Accelerated Approval From FDA
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
The Three-year Loss for Pfizer (NYSE:PFE) Shareholders Likely Driven by Its Shrinking Earnings
Express News | FDA Says Hospira's Ketamine Hydrochloride, Injection, 500 Mg/10 Ml (50 Mg/Ml) (Ndc 0409-2053-10) Currently Unavailable - Website
Pfizer Options Spot-On: On December 20th, 288.48K Contracts Were Traded, With 3.77 Million Open Interest
Friday Market Rebounds Some of Weeks Loss | Wall Street Today
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Sector Update: Health Care
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Pfizer Drug Combination to Treat Colorectal Cancer Cleared by FDA